Clinical study demonstrates faster, more consistent diagnostic reporting when AI is integrated directly into the pathology viewer

PathPresenter, developer of an industry-leading vendor-neutral digital pathology Image Management System (IMS), and Primaa, developer of AI solutions for dermatopathology including the Cleo Skin product, today announced the successful completion of a collaborative validation study on the integration of AI into pathologists’ daily workflow. The results demonstrate improved diagnostic performance as well as faster and more consistent reporting.

The companies will present the complete study results and demonstrate the validated pathology workflow during a live webinar on Tuesday, September 22, 2026, at 11:00 a.m. Eastern Time.

Unlike many studies that evaluate AI algorithms independently, this research examined AI as part of an integrated diagnostic workflow in which the Cleo Skin analysis appears directly within the PathPresenter viewer, automatically populating structured reporting fields, and enabling pathology reports to be generated with a few keystrokes or even a single click using macro codes. Measurements such as Breslow thickness and mitotic counts are transferred automatically into the report, reducing manual documentation while helping standardize reporting across pathologists. This makes it one of the first AI tools for skin pathology to be tested fully integrated within a digital pathology viewer, with semi-automated reporting built directly into the pathologist’s existing workflow.

Using a two-phase crossover study involving 75 whole-slide images interpreted by seven investigator pathologists, the study compared conventional digital pathology review with the integrated AI-assisted workflow after a four-week washout period.

Cleo Skin is already CE-IVDR certified based on Primaa’s clinical validation studies; this U.S. study complements that clinical evidence, confirming similar results among U.S. pathologists. PathPresenter’s clinical viewer carries both FDA 510(k) clearance and CE-IVDR certification.

The final results demonstrated measurable improvements in both diagnostic performance and workflow efficiency:

• 20% reduction in analysis time
• 17% improvement in diagnostic sensitivity among junior pathologists, highlighting the workflow’s greatest benefit among less experienced readers.

Additional findings, including gains in overall diagnostic sensitivity and immunohistochemistry request rates, will be presented in full during the September 22 webinar.

The study also showed improved performance in melanoma assessment, including reduced Breslow misclassification rates, higher clinical sensitivity, and improved overall diagnostic accuracy.

“Artificial intelligence delivers its greatest value when it becomes a natural extension of the pathologist’s workflow rather than another application to consult,” said Dr. Rajendra Singh, Associate Vice Chair of Pathology at the University of Pennsylvania and PathPresenter co-founder. “This study demonstrates that integrating AI directly into the enterprise image management system can improve both efficiency and diagnostic performance while preserving the pathologist’s central role in clinical decision-making.”

Hugo Watel , COO of Primaa, added, “This partnership reflects why we built Primaa: pathologists are under growing pressure, and AI needs to fit into their workflow to actually help. Integrating Cleo Skin directly into PathPresenter’s platform means it becomes part of pathologists’ daily routine. That everyday use is what makes the impact real: time saved, greater confidence in their practice, and a smoother-running organization.”

Webinar: Final Clinical Results and Workflow Demonstration

During the webinar, Dr. Singh and Mr. Watel will present the study methodology, review the final clinical outcomes, and walk through the integrated workflow used throughout the study. Attendees will gain insight into how AI-assisted reporting can be incorporated into routine dermatopathology practice while improving efficiency and maintaining clinician oversight.

From AI to Clinical Workflow: Validating AI-Assisted Dermatopathology with Primaa and PathPresenter

Date: Tuesday, September 22, 2026

Time: 11:00 a.m. Eastern Time

Register: AI-Assisted Dermatopathology Workflow Validation Study

Live Demonstrations at Pathology Visions 2026

Those interested in seeing these solutions in person are invited to meet with Primaa and PathPresenter for live demonstrations at Pathology Visions 2026 in San Diego, October 16-18.

About PathPresenter

PathPresenter is the industry’s leading vendor-neutral Image Management System (IMS) for digital pathology. The platform brings together primary diagnosis, remote consultation, image biorepository management, enterprise education, and AI integration in a single interoperable environment, helping pathology organizations streamline workflows while maximizing flexibility, interoperability, and return on investment.

About Primaa

Primaa is a leading provider of integrated AI solutions dedicated to enhance the accuracy and efficiency of biomarker detection in dermatopathology and breast pathology. Its flagship tools, Cleo Breast and Cleo Skin, support pathologists in delivering faster and more reliable diagnoses, ultimately redefining how tissue lesions are assessed.